PubRank

World journal of gastrointestinal pharmacology and therapeutics (World J Gastrointest Pharmacol Ther)

Journal PubWeight™ 150.88‹?›

Top papers

Rank Title Year PubWeight™‹?›
1 Henoch-Schönlein purpura complicating adalimumab therapy for Crohn's disease. 2010 1.00
2 Esophageal motility abnormalities in gastroesophageal reflux disease. 2014 0.99
3 Helicobacter pylori therapy: Present and future. 2012 0.97
4 Lactose malabsorption and intolerance: What should be the best clinical management? 2012 0.96
5 Transoral incisionless fundoplication for gastro-esophageal reflux disease: Techniques and outcomes. 2016 0.95
6 Diagnosis and treatment of gastroesophageal reflux disease. 2014 0.95
7 Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan. 2012 0.95
8 Identifying the best therapy for chronic anal fissure. 2011 0.94
9 Aspirin, cyclooxygenase inhibition and colorectal cancer. 2014 0.92
10 Role of macrophages in the progression of acute pancreatitis. 2010 0.92
11 Therapy of gallstone disease: What it was, what it is, what it will be. 2012 0.90
12 Prevention of hepatocellular carcinoma in patients with chronic hepatitis B. 2014 0.88
13 Validation of methods to assess potential biomarkers in pediatric patients with esophageal eosinophilia. 2013 0.88
14 Rifaximin therapy and hepatic encephalopathy: Pros and cons. 2012 0.87
15 Intestinal pseudo-obstruction in inactive systemic lupus erythematosus: An unusual finding. 2010 0.87
16 Metabolomics as a diagnostic tool in gastroenterology. 2013 0.87
17 Visceral hypersensitivity and electromechanical dysfunction as therapeutic targets in pediatric functional dyspepsia. 2014 0.86
18 Stress ulcer prophylaxis guidelines: Are they being implemented in Lebanese health care centers? 2011 0.86
19 Eosinophils and mast cells as therapeutic targets in pediatric functional dyspepsia. 2013 0.86
20 Proton pump inhibitor-associated pneumonia: Not a breath of fresh air after all? 2011 0.85
21 Which is the best choice for gastroesophageal disorders: Melatonin or proton pump inhibitors? 2010 0.84
22 Reduced esophageal cancer incidence in statin users, particularly with cyclo-oxygenase inhibition. 2013 0.84
23 Overview of cytokines and nitric oxide involvement in immuno-pathogenesis of inflammatory bowel diseases. 2016 0.84
24 Z α-1 antitrypsin deficiency and the endoplasmic reticulum stress response. 2010 0.83
25 Diverticular disease: A therapeutic overview. 2010 0.83
26 Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis. 2015 0.83
27 Mesalamine induced symptom exacerbation of ulcerative colitis: Case report and brief discussion. 2010 0.82
28 Diagnosis and therapy of non-variceal upper gastrointestinal bleeding. 2015 0.82
29 Inflammatory bowel disease: An archetype disorder of outer environment sensor systems. 2013 0.82
30 Present state and future challenges in pediatric abdominal pain therapeutics research: Looking beyond the forest. 2015 0.81
31 Use of acid suppressive therapy in hospitalized non-critically ill patients. 2012 0.81
32 Clinical update for the diagnosis and treatment of Clostridium difficile infection. 2014 0.81
33 Management practices of hepatitis C virus infected alcoholic hepatitis patients: A survey of physicians. 2013 0.81
34 Helicobacter pylori and its reservoirs: A correlation with the gastric infection. 2016 0.81
35 Antioxidants in liver health. 2015 0.80
36 Ethanol consumption as inductor of pancreatitis. 2010 0.80
37 Endoscopic ultrasonography: Challenges and opportunities in the developing world. 2014 0.80
38 Antidepressants can treat inflammatory bowel disease through regulation of the nuclear factor-κB/nitric oxide pathway and inhibition of cytokine production: A hypothesis. 2012 0.80
39 Renal dysfunction in patients with cirrhosis: Where do we stand? 2014 0.80
40 Gastrointestinal Kaposi's sarcoma: Case report and review of the literature. 2015 0.80
41 Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett's esophagus. 2014 0.80
42 Antibiotic treatment for Helicobacter pylori: Is the end coming? 2015 0.80
43 Influence of environmental factors in the development of inflammatory bowel diseases. 2016 0.80
44 Local ablative treatments for hepatocellular carcinoma: An updated review. 2016 0.80
45 Intestinal neuronal dysplasia type B: A still little known diagnosis for organic causes of intestinal chronic constipation. 2016 0.79
46 Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. 2016 0.79
47 Standard triple versus levofloxacin based regimen for eradication of Helicobacter pylori. 2013 0.79
48 Inflammatory bowel diseases: Current problems and future tasks. 2014 0.79
49 Antifibrotic effect of heparin on liver fibrosis model in rats. 2012 0.79
50 Understanding and treating refractory constipation. 2014 0.79
Next 50